logo Research, Innovation and Dissemination Centers

Center for Cell-Based Therapy

CEPID 2001-2013
CEPID 2013-2024
Website: http://ctcusp.org
Principal investigator: Dimas Tadeu Covas
Education and knowledge diffusion coordinator: Marisa Ramos Barbieri
Technology transfer coordinator: Flávio Vieira Meirelles
University of São Paulo (USP)
Fundação Hemocentro de Ribeirão Preto
Rua Tenente Catão Roxo, 2.501
14051-140 - Ribeirão Preto, SP - Brasil
Federal University of São Carlos (UFSCAR)
Hemotherapy Center of Ribeirão Preto (FUNDHERP)
King's College, United Kingdom
Leiden University, Netherlands
Northwestern University, USA
Paris University, France
São Paulo State University (UNESP)
University of California, USA
University of Feinberg, USA
University of Guelph, Canada
University of Montreal, Canada
University of Munchen, Germany
University of Oxford, United Kingdom
University of Southern California, USA

BV-FAPESP: research projects supported in this Center 

CTC in the Media: news about the Center


The Center for Cell-based Therapy (CTC) is made up of a group of researchers of USP and of the Regional Blood Center of Ribeirão Preto who are interested in understanding the biology of stem cells, as well as in developing new technology for their use in the treatment of diseases. The group of researchers engages physicians, biologists, biomedical professionals, pharmacists, and veterinarians, among others, that worked together since 2000.

The researchers at CTC were responsible for the generation of the first embryonic stem cell line in Brazil and produced one of the first bovine and ovine clones in the country.

In the laboratory, CTC researchers have an interest in signaling pathways of mammalian and human embryonic stem cells, in animal and human adult cells reprogramming to the embryonic state of pluripotency (iPS cells) and in the functioning of adult stem cells, such as hematopoietic, mesenchymal and cancer stem cells.

From stem cells derived from healthy people, CTC scientists investigate ways of producing blood components as an alternative source of blood transfusion. In the laboratory, other researchers use iPS cells derived from patients with blood disorders to better understand how these diseases happen and how they could be prevented or better treated.

In the clinical area, researcher-physicians develop new methods of diagnosis and new treatment for leukemia, and also use new stem cells, like mesenchymal stem cells, for the treatment of many diseases, such as diabetes mellitus, systemic sclerosis, and aplastic anemia. CTC relies upon laboratories of cell and molecular biology and cell culture and inpatient units of hematopoietic stem cell transplantation in Ribeirão Preto, Pirassununga, and São Paulo.

Research conducted within the Cell Therapy Center, USP (CTC) as to bring benefits to Brazilian society the possibility of obtaining more efficient medications, developed with Brazilian technology.

Among the advances made, in the past few years, divulged by the press and scientific journals, we highlight the development of a platform for expanding genetically modified T cells for treating patients with leukemia and lymphomas; the discovery of the onset of X chromosome inactivation during human embryonic development; the advances in the treatment of systemic and multiple sclerosis; the new perspectives on fighting one of the most aggressive types of brain tumor, astrocytoma; the inhibition of melanoma cells in culture; studies on telomeres; and the formation of a cell bank with the genetics of the Brazilian population.